Atlas Trials

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Clinical trial NCT06255223 · RECRUITING

Trial details

NCT number
NCT06255223
Sponsor
Jinling Hospital, China
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor
Start date
2023-12-15
Primary completion
2026-09-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.